Overcoming immunosuppression to enhance a p53MVA vaccine

p53MVA Therapy in Patients with Refractory Gastrointestinal Malignancies Elevates p53-Specific CD8+ T-cell Responses

(2014) N. R. Hardwick et al.   CLINICAL CANCER RESEARCH

Changes in the immune cell population and cell proliferation in peripheral blood after gemcitabine-based chemotherapy for pancreatic cancer

(2013) Y. Homma et al.   Clinical & Translational Oncology

Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity

(2012) Suzanne L Topalian et al.   CURRENT OPINION IN IMMUNOLOGY

Potentiation of a p53-SLP vaccine by cyclophosphamide in ovarian cancer: A single-arm phase II study

(2011) Renee Vermeij et al.   INTERNATIONAL JOURNAL OF CANCER

Phase 1 Trial of Wilms Tumor 1 (WT1) Peptide Vaccine and Gemcitabine Combination Therapy in Patients With Advanced Pancreatic or Biliary Tract Cancer

(2010) Miho Kaida et al.   JOURNAL OF IMMUNOTHERAPY

Semi Mature Blood Dendritic Cells Exist in Patients with Ductal Pancreatic Adenocarcinoma Owing to Inflammatory Factors Released from the Tumor

(2010) Vegard Tjomsland et al.   PLoS One

Immunization with a P53 synthetic long peptide vaccine induces P53-specific immune responses in ovarian cancer patients, a phase II trial

(2009) Ninke Leffers et al.   INTERNATIONAL JOURNAL OF CANCER

Regular Dose of Gemcitabine Induces an Increase in CD14+ Monocytes and CD11c+ Dendritic Cells in Patients with Advanced Pancreatic Cancer

(2009) Atsuko Soeda et al.   JAPANESE JOURNAL OF CLINICAL ONCOLOGY

A Combination Therapy of Gemcitabine With Immunotherapy for Patients With Inoperable Locally Advanced Pancreatic Cancer

(2009) Yoshiki Hirooka et al.   PANCREAS